Harnessing T cells to fight cancer with BiTE®antibody constructs - past developments and future directions
出版年份 2016 全文链接
标题
Harnessing T cells to fight cancer with BiTE®antibody constructs - past developments and future directions
作者
关键词
-
出版物
IMMUNOLOGICAL REVIEWS
Volume 270, Issue 1, Pages 193-208
出版商
Wiley
发表日期
2016-02-12
DOI
10.1111/imr.12393
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology
- (2015) Meagan S. Barbee et al. ANNALS OF PHARMACOTHERAPY
- Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing
- (2015) D. M. Kurtz et al. BLOOD
- CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1
- (2015) Takuya Osada et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer
- (2015) Julia Stieglmaier et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- VIII. Treatment of chronic lymphocytic leukaemia, where are we heading?
- (2015) Susan M. O'Brien HEMATOLOGICAL ONCOLOGY
- T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment
- (2015) Frauke M. Schnorfeil et al. Journal of Hematology & Oncology
- Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street
- (2015) David M. Barrett et al. JOURNAL OF IMMUNOLOGY
- Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study
- (2015) Mark Roschewski et al. LANCET ONCOLOGY
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells
- (2015) Annie A Wu et al. OncoImmunology
- The past and future of CD33 as therapeutic target in acute myeloid leukemia
- (2014) George S. Laszlo et al. BLOOD REVIEWS
- Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
- (2014) Tatyana Feldman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Emerging roles of regulatory T cells in tumour progression and metastasis
- (2014) Elizabeth C. Halvorsen et al. CANCER AND METASTASIS REVIEWS
- Trafficking of T Cells into Tumors
- (2014) C. Y. Slaney et al. CANCER RESEARCH
- New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape
- (2014) Deepak Mittal et al. CURRENT OPINION IN IMMUNOLOGY
- 535 Tumor targeting and tissue distribution of solitomab (AMG 110; anti-EpCAM BiTE®) in human EpCAM-positive tumor bearing mice
- (2014) F.J. Warnders et al. EUROPEAN JOURNAL OF CANCER
- Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
- (2014) P. Schlegel et al. HAEMATOLOGICA
- Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
- (2014) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas
- (2014) Michael D Oberst et al. mAbs
- Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell-Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia
- (2014) M. Friedrich et al. MOLECULAR CANCER THERAPEUTICS
- Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia
- (2014) G Zugmaier et al. Blood Cancer Journal
- CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
- (2013) C. Krupka et al. BLOOD
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML
- (2013) G. S. Laszlo et al. BLOOD
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
- (2012) M. Klinger et al. BLOOD
- Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
- (2012) M. S. Topp et al. BLOOD
- Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
- (2012) R. B. Walter et al. BLOOD
- Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies
- (2012) N. Gokbuget et al. BLOOD
- Abstract 4841: Lysis of cancer cells by highly purified T regulatory cells engaged via an EpCAM/CD3-bispecific BiTE antibody
- (2012) Markus Münz et al. CANCER RESEARCH
- Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
- (2012) Stephen P. Hunger et al. JOURNAL OF CLINICAL ONCOLOGY
- High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia
- (2012) Susan O'Brien et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
- (2012) M. Friedrich et al. MOLECULAR CANCER THERAPEUTICS
- Blinatumomab: A historical perspective
- (2012) Dirk Nagorsen et al. PHARMACOLOGY & THERAPEUTICS
- Protecting a serial killer: pathways for perforin trafficking and self-defence ensure sequential target cell death
- (2012) Jamie A. Lopez et al. TRENDS IN IMMUNOLOGY
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
- (2011) Dirk Nagorsen et al. EXPERIMENTAL CELL RESEARCH
- Modern Therapy of Acute Lymphoblastic Leukemia
- (2011) Renato Bassan et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
- (2011) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases
- (2011) Sara Raponi et al. LEUKEMIA & LYMPHOMA
- Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110
- (2011) Silke Petsch et al. mAbs
- How I treat acute myeloid leukemia
- (2010) J. M. Rowe et al. BLOOD
- Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration
- (2010) Hagop M. Kantarjian et al. CANCER
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
- (2010) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia
- (2010) R Handgretinger et al. LEUKEMIA
- T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
- (2010) Ralf Lutterbuese et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
- (2009) T Osada et al. BRITISH JOURNAL OF CANCER
- The Emerging Role of EpCAM in Cancer and Stem Cell Signaling
- (2009) M. Munz et al. CANCER RESEARCH
- Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
- (2009) Cornelia Haas et al. IMMUNOBIOLOGY
- Antitumor Activity of an EpCAM/CD3-bispecific BiTE Antibody During Long-term Treatment of Mice in the Absence of T-cell Anergy and Sustained Cytokine Release
- (2009) Maria Amann et al. JOURNAL OF IMMUNOTHERAPY
- Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA
- (2009) Ralf Lutterbuese et al. JOURNAL OF IMMUNOTHERAPY
- Nuclear signalling by tumour-associated antigen EpCAM
- (2009) Dorothea Maetzel et al. NATURE CELL BIOLOGY
- The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival
- (2008) D. O'Shea et al. BLOOD
- Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century
- (2008) D. Pulte et al. BLOOD
- Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans
- (2008) Maria Amann et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma
- (2008) Kai Fu et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells
- (2008) Sandrine d’Argouges et al. LEUKEMIA RESEARCH
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started